TP53 R72P and MDM2 SNP309 polymorphisms and colorectal cancer risk: The Fukuoka Colorectal Cancer Study

Japanese Journal of Clinical Oncology

Volumn 41, Issue 2, 2011, Pages 232-238

  Joshi, Amit Man ^a   Budhathoki, Sanjeev ^a   Ohnaka, Keizo ^a   Mibu, Ryuichi ^a   Tanaka, Masao ^a   Kakeji, Yoshihiro ^a   Maehara, Yoshihiko ^a   Okamura, Takeshi ^b   Ikejiri, Koji ^c   Futami, Kitaroh ^d   Maekawa, Takafumi ^d   Yasunami, Yohichi ^e  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^d Fukuoka University Chikushi Hospital   (Japan)

^e FUKUOKA UNIVERSITY   (Japan)

Author keywords

Colorectal cancers; MDM2 SNP309; Polymorphism; TP53 R72P

Indexed keywords

ARGININE; GUANINE; PROLINE; PROTEIN MDM2; PROTEIN P53; THYMINE;

ADULT; AGE DISTRIBUTION; AGED; ALLELE; ARTICLE; CANCER RISK; CODON; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION BASED CASE CONTROL STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 79251645931     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq200     Document Type: Article

References (35)

1. Whibley C, Pharoah PDP, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009;9:95-107.
2. Själander A, Birgander R, Athlin L, Stenling R, Rutegard J, Beckman L, et al. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 1995;16:1461-4.
3. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Guitierrez-Enriquez S, et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004;23:1954-6.
4. Zhu ZZ, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, et al. Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol 2007;37:385-90.
5. Cao Z, Song JH, Park YK, Maeng EJ, Nam SW, Lee JY, et al. The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma 2009;56:114-8.
6. Olschwang S, Laurent-Puig P, Vassal A, Salmon RJ, Thomas G. Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Hum Genet 1991;86:369-70.
7. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993;14:1085-9.
8. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 1996;17:261-4.
9. Sayhan N, Yazici H, Budak M, Bitisik O, Dalay N. P53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol 2001;109:25-34.
10. Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Hatooka S, et al. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 2002;181:81-5.
11. Pérez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006;12:1426-9.
12. Koushik A, Tranah GJ, Ma J, Stampfer MJ, Sesso HD, Fuchs CS, et al. p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 2006;119:1863-8.
13. Dakouras A, Nikiteas N, Papadakis E, Perakis M, Valis D, Rallis G, et al. p53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population. Anticancer Res 2008;28:1039-44.
14. Csejtei A, Tibold A, Varga Z, Koltai K, Ember A, Orsos Z, et al. GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer Res 2008;28:1917-22.
15. Mammano E, Belluco C, Bonafé M, Olivieri F, Mugianesi E, Barbi C, et al. Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression. Eur J Surg Oncol 2009;35:415-9.
16. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
17. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2006;43:531-3.
18. Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomaki K, Pruntel R, et al. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 2007;15:110-4.
19. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006;98:285-8.
20. Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 2007;28:2262-7.
21. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FBL, Tollenaar RAEM, et al. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the Breast Cancer Association Consortium. Cancer Res 2007;67:9584-90.
22. Horikawa Y, Nadaoka J, Saito M, Kumazawa T, Inoue T, Yuasa T, et al. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep 2008;20:49-55.
23. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. MDM2 SNP309 T. > G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer 2007;120:563-65.
24. Kono S, Toyomura K, Yin G, Nagano J, Mizoue T. A case-control study of colorectal cancer in relation to lifestyle factors and genetic polymorphisms: design and conduct of the Fukuoka colorectal cancer study. Asian Pac J Cancer Prev 2004;5:393-400.
25. Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, et al. Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol 2006;100:173-8.
26. Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 2007;104:660-4.
27. Alhopuro P, Ylisaukko-oja SK, Koskinen WJ, Bono P, Arola J, Jarvinen HJ, et al. MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 2005;42:694-8.
28. Alazzouzi H, Suriano G, Guerra A, Plaja A, Espín E, Armengol M, et al. Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells. J Med Genet 2007;44:75-80.
29. Sotamaa K, Liyanarachchi S, Mecklin JP, Jarvinen H, Aaltonen LA, Peltomaki P, et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 2005;11:6840-4.
30. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 2007;26:1317-23.
31. Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ. MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 2006;43:950-2.
32. Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol 2004;88:261-6.
33. Curtin K, Lin WY, George R, Katory M, Shorto J, Cannon-Albright LA, et al. Meta association of colorectal cancer confirms risk alleles at 8q24 and 18q21. Cancer Epidemiol Biomarkers Prev 2009;18:616-21.
34. Tenesa A, Theodoratou E, Din FV, Farrington SM, Cetnarskyj R, Barnetson RA, et al. Ten common genetic variants associated with colorectal cancer risk are not associated with survival after diagnosis. Clin Cancer Res 2010;16:3754-9.
35. Sjölander A, Birgander R, Saha N, Beckman L, Beckman G. p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Hum Hered 1996;46:41-8.